Using BiXAbTM, a novel tetravalent, bispecific antibody format platform, we explored the positioning and activity of Fabs targeting the ErbB family of RTKs with the aim of identifying candidates that could potentially be used for pancreatic cancer treatment. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.